Trial redesign for the phase II/III DETECTION trial: circulating tumour DNA-guided therapy for stage IIB/C melanoma after surgical resection

被引：1

作者：

Muinonen-Martin, Andy ^{[1
]}

Lee, Rebecca ^{[2
,3
]}

Rothwell, Dominic ^{[4
]}

Jackson, Richard ^{[5
]}

Smith, Nigel ^{[4
]}

Wong, Stephen ^{[6
,7
]}

Kelso, Noel ^{[4
]}

Hewitt, Chelsee ^{[6
]}

Mitchell, Jackie ^{[4
]}

Jones, Kate ^{[6
]}

Turajlic, Samra ^{[8
]}

Corrie, Pippa ^{[9
]}

Marais, Richard ^{[10
]}

Middleton, Mark ^{[11
]}

Dawson, Sarah-Jane ^{[6
,7
,12
]}

Sandhu, Shahneen ^{[6
,7
]}

Dive, Caroline ^{[4
]}

Lorrigan, Paul ^{[2
]}

机构：

[1] Leeds Teaching Hosp NHS Trust, Leeds, England

[2] Christie NHS Fdn Trust, Manchester, England

[3] Div Canc Sci, Manchester, Lancs, England

[4] Canc Res UK Manchester Inst, Canc Biomarker Ctr, Manchester, Lancs, England

[5] Univ Liverpool, Liverpool Clin Trials Unit, Liverpool, England

[6] Peter MacCallum Canc Ctr, Melbourne, Australia

[7] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Australia

[8] Royal Marsden Hosp, Dept Med Oncol, London, England

[9] Cambridge Univ Hosp NHS Fdn Trust, Cambridge, England

[10] Univ Manchester, Manchester Inst, Mol Oncol Grp, Canc Biomarker Ctr, Manchester, England

[11] Churchill Hosp, Dept Med Oncol, Oxford, England

[12] Univ Melbourne, Ctr Canc Res, Melbourne, Australia

来源：

BRITISH JOURNAL OF DERMATOLOGY | 2023年 / 188卷

关键词：

D O I：

10.1093/bjd/ljad113.084

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

P56

引用

页数：1

共 50 条

[41] A phase III trial to confirm the superiority of S-1 adjuvant chemotherapy for vulnerable elderly patients with pathological stage II/III gastric cancer after curative resection: JCOG1507 (BIRDIE).
Yamaguchi, Kazuya
Yoshida, Kazuhiro
Mizusawa, Junki
Mizutani, Tomonori
Ito, Seiji
Nishida, Yasunori
Yabusaki, Hiroshi
Sano, Takeshi
Sasako, Mitsuru
Katayama, Hiroshi
Fukuda, Haruhiko
Boku, Narikazu
Yoshikawa, Takaki
Terashima, Masanori
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
[42] Circulating-tumour DNA (ctDNA) detection using an ultra-sensitive next generation sequencing (NGS)-based assay in patients with resected colorectal cancer (CRC) in the phase III ASCOLT trial
Day, D.
Starus, A.
Sieber, O.
Prasse, D.
Lamik, A.
Fredebohm, J.
Simes, J.
Day, F.
Jeffery, M.
Zielinski, R.
Singh, M.
Chong, G.
Li, S.
Mouradov, D.
Chia, J.
Ali, R.
Toh, H.
Jones, F.
Segelov, E.
ANNALS OF ONCOLOGY, 2022, 33 : S282 - S283
[43] Circulating-tumour DNA (ctDNA) detection using an ultra-sensitive next generation sequencing (NGS)-based assay in patients with resected colorectal cancer (CRC) in the phase III ASCOLT trial
Day, Daphne
Starus, Anna
Sieber, Oliver
Prasse, Daniela
Lamik, Agathe
Fredebohm, Johannes
Simes, John
Day, Fiona
Jeffery, Mark
Zielinski, Robert
Singh, Madhu
Chong, Geoffrey
Shan, Li
Mouradov, Dmitri
Chia, John W. K.
Ali, Raghib
Toh, Han Chong
Jones, Frederick
Segelov, Eva
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 120 - 121
[44] Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma
Eggermont, Alexander M. M.
Meshcheryakov, Andrey
Atkinson, Victoria
Blank, Christian U.
Mandala, Mario
Long, Georgina, V
Barrow, Catherine
Di Giacomo, Anna Maria
Fisher, Rosalie
Sandhu, Shahneen
Kudchadkar, Ragini
Romero, Pablo Luis Ortiz
Svane, Inge Marie
Larkin, James
Puig, Susana
Hersey, Peter
Quaglino, Pietro
Queirolo, Paola
Stroyakovskiy, Daniil
Bastholt, Lars
Mohr, Peter
Hernberg, Micaela
Chiarion-Sileni, Vanna
Strother, Matthew
Hauschild, Axel
Yamazaki, Naoya
van Akkooi, Alexander Cj
Lorigan, Paul
Krepler, Clemens
Ibrahim, Nageatte
Marreaud, Sandrine
Kicinski, Michal
Suciu, Stefan
Robert, Caroline
EUROPEAN JOURNAL OF CANCER, 2021, 158 : 156 - 168
[45] Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Efficacy and safety results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial
Eggermont, Alexander M.
Blank, Christian U.
Mandala, Mario
Long, Georgina V.
Atkinson, Victoria
Dalle, Stephane
Haydon, Andrew
Lichinitser, Mikhail
Khattak, Adnan
Carlino, Matteo S.
Sandhu, Shahneen
Larkin, James
Puig, Susana
Ascierto, Paolo A.
Rutkowski, Piotr
Schadendorf, Dirk
Koornstra, Rutger
Hernandez-Aya, Leonel
Maio, Michele
van den Eertwegh, Alfonsus J.
Grob, Jean-Jacques
Gutzmer, Ralf
Jamal, Rahima
Rivas, Veronica
Ibrahim, Nageatte
Marreaud, Sandrine
Janssen, Sven
van Akkooi, Alexander
Suciu, Stefan
Robert, Caroline
CANCER RESEARCH, 2018, 78 (13)
[46] Ipilimumab (IPI) vs placebo (PBO) after complete resection of stage III melanoma: final overall survival results from the EORTC 18071 randomized, double-blind, phase 3 trial
Eggermont, A. M. M.
Chiarion-Sileni, V.
Grob, J-J.
Dummer, R.
Wolchok, J. D.
Schmidt, H.
Hamid, O.
Robert, C.
Ascierto, P. A.
Richards, J. M.
Lebbe, C.
Ferraresi, V.
Smylie, M.
Weber, J. S.
Taitt, C.
de Pril, V.
de Schaetzen, G.
Suciu, S.
Testori, A.
ANNALS OF ONCOLOGY, 2016, 27
[47] Results from a Single Institution Phase II Trial of Concurrent Docetaxel/Carboplatin/Radiotherapy Followed by Surgical Resection and Consolidation Docetaxel/Carboplatin in Stage III Non-Small-Cell Lung Cancer
Das, Millie
Donington, Jessica S.
Murphy, James
Kozak, Margaret
Eclov, Neville
Whyte, Richard I.
Hoang, Chuong D.
Zhou, Lisa
Le, Quynh-Thu
Loo, Billy W., Jr.
Wakelee, Heather
CLINICAL LUNG CANCER, 2011, 12 (05) : 280 - 285
[48] Adjuvant Ganglioside GM2-KLH/QS-21 Vaccination Versus Observation After Resection of Primary Tumor > 1.5 mm in Patients With Stage II Melanoma: Results of the EORTC 18961 Randomized Phase III Trial
Eggermont, Alexander M. M.
Suciu, Stefan
Rutkowski, Piotr
Marsden, Jeremy
Santinami, Mario
Corrie, Philippa
Aamdal, Steinar
Ascierto, Paolo A.
Patel, Poulam M.
Kruit, Wim H.
Bastholt, Lars
Borgognoni, Lorenzo
Bernengo, Maria Grazia
Davidson, Neville
Polders, Larissa
Praet, Michel
Spatz, Alan
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (30) : 3831 - +
[49] Health-related quality-of-life results for pembrolizumab versus placebo after complete resection of high-risk stage III melanoma from the EORTC 1325-MG/Keynote 054 trial: An international randomized double-blind phase III trial
Coens, C.
Bottomley, A.
Blank, C. U.
Mandala, M.
Long, G. V.
Atkinson, V. G.
Dalle, S.
Haydon, A.
Lichinitser, M.
Khattak, A.
Carlino, M. S.
Sandhu, S. K.
Larkin, J.
Puig Sarda, S.
Ascierto, P. A.
Schadendorf, D.
Ibrahim, N.
Suciu, S.
Robert, C.
Eggermont, A. M. M.
ANNALS OF ONCOLOGY, 2018, 29 : 456 - 456
[50] Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: 5-year results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial
Eggermont, A. M. M.
Kicinski, M.
Blank, C. U.
Mandala, M.
Long, G. V.
Atkinson, V. G.
Dalle, S.
Haydon, A. M.
Meshcheryakov, A.
Khattak, A.
Carlino, M. S.
Sandhu, S. K.
Sarda, S. S. Puig
Ascierto, P. A.
Lorigan, P.
Grebennik, D.
Ibrahim, N.
Marreaud, S. I.
Suciu, S.
Robert, C.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S912 - S913

← 1 2 3 4 5 →